Australian biopharmaceutical company Servatus has appointed an experienced senior global Boehringer Ingelheim executive to its board of directors.
Servatus was established in 2012 as a company focused on developing novel autoimmune and microbiome therapies.
It has been announced that Dr Uwe Buecheler has joined its board as a non-executive director.
Dr Buecheler is a leading molecular biologist with over 30 years of biopharmaceutical experience with the German company Boehringer Ingelheim.
The company said Dr Buecheler's appointment comes at a significant time as it progresses its clinical trial program, including studies of its investigative candidates in irritable bowel syndrome, insomnia, rheumatoid arthritis and other health problems associated with the gut-microbiome-brain axis.
Dr Buecheler joined Boehringer Ingelheim in 1991 and currently serves as a senior advisor for biopharmaceuticals to its Board of Management Directors.
During his extensive career at Boehringer Ingelheim, Dr Buecheler has held a variety of senior roles across development, regulatory, biosafety, and quality, and as the site head and lead for an expansion of the company's operations in Europe, the US and China.
Dr Buecheler has overseen more than 30 biologic product approvals and launches, including more than five top 20 global biopharmaceuticals.
Servatus CEO Dr Wayne Finlayson said, “We are thrilled to have Dr Uwe Buecheler join our Board as Non-Executive Director. Uwe brings extensive scientific and commercial leadership as well as invaluable experience in developing global biopharmaceutical operations. His appointment will significantly strengthen our Board capabilities and further complement the high-calibre team Servatus has drawn from around the world as we look to advance development of our market-leading biotherapeutics programs.
"We hope to leverage Uwe’s vast knowledge and experience gained throughout his many years at Boehringer Ingelheim, one of the world’s top pharmaceutical companies, while expanding Servatus’ core business units over the next three years.”
Dr Uwe Buecheler added, “I am delighted to join Servatus’ Board during an exciting period of growth for the Company. Servatus is backed by a highly experienced and credible team that is at the forefront of microbial biotherapeutics and it is an honour for me to take up this opportunity to help contribute to the growth of Servatus during a pivotal time in the company’s history. I look forward to delivering on our objectives to maximise the global expansion capabilities of this leading business over the next three years and beyond.”